Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Latilactobacillus sakei LB-P12
- Development stage
- Unknown
- Lead developer
- LISCure Biosciences
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Latilactobacillus sakei LB-P12 is a specific probiotic strain isolated from kimchi, currently under investigation for its therapeutic potential in managing knee osteoarthritis (OA). The drug operates via the gut-joint axis, where it modulates the host's immune response and systemic inflammation. Preclinical studies in rat models and an exploratory Phase 2 randomized controlled trial have demonstrated that LB-P12 significantly reduces chronic knee pain, stiffness, and physical limitations. Mechanistically, it suppresses the nuclear factor-κB (NF-κB) and hypoxia-inducible factor-2α (HIF-2α) signaling pathways, which are critical regulators of inflammation and cartilage degradation. This suppression leads to a decrease in pro-inflammatory mediators such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2), as well as the catabolic enzyme matrix metalloproteinase 13 (MMP-13). LB-P12 is administered orally at a daily dose of 10 billion CFU and has shown a favorable safety profile with no reported adverse events.
- Other names
- L. sakei LB-P12Latilactobacillus sakei strain LB-P12
02
Targets
EPAS1 (Hypoxia-inducible factor 2-alpha)MMP13 (Matrix metalloproteinase-13)NF-κB
Beyond the preview
Go deeper on Latilactobacillus sakei LB-P12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Latilactobacillus sakei LB-P12.